Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using 64Cu-labeled daratumumab.

Li S, England CG, Ehlerding EB, Kutyreff CJ, Engle JW, Jiang D, Cai W.

Am J Transl Res. 2019 Sep 15;11(9):6007-6015. eCollection 2019.

2.

DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury.

Jiang D, Ge Z, Im HJ, England CG, Ni D, Hou J, Zhang L, Kutyreff CJ, Yan Y, Liu Y, Cho SY, Engle JW, Shi J, Huang P, Fan C, Yan H, Cai W.

Nat Biomed Eng. 2018 Nov;2(11):865-877. doi: 10.1038/s41551-018-0317-8. Epub 2018 Nov 8.

3.

Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.

Liu B, Jones M, Kong L, Noel T, Jeng EK, Shi S, England CG, Alter S, Miller JS, Cai W, Rhode PR, Wong HC.

Cytokine. 2018 Jul;107:105-112. doi: 10.1016/j.cyto.2017.12.003. Epub 2018 Feb 13.

4.

ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.

Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, Wang R, Engle JW, Xu X, Huang P, Cai W.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1372-1381. doi: 10.1007/s00259-018-3941-3. Epub 2018 Feb 15.

5.

Renal-Clearable PEGylated Porphyrin Nanoparticles for Image-guided Photodynamic Cancer Therapy.

Cheng L, Jiang D, Kamkaew A, Valdovinos HF, Im HJ, Feng L, England CG, Goel S, Barnhart TE, Liu Z, Cai W.

Adv Funct Mater. 2017 Sep 13;27(34). pii: 1702928. doi: 10.1002/adfm.201702928. Epub 2017 Jul 26.

6.

ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.

Hernandez R, England CG, Yang Y, Valdovinos HF, Liu B, Wong HC, Barnhart TE, Cai W.

J Control Release. 2017 Oct 28;264:160-168. doi: 10.1016/j.jconrel.2017.08.029. Epub 2017 Aug 24.

7.

ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.

England CG, Jiang D, Hernandez R, Sun H, Valdovinos HF, Ehlerding EB, Engle JW, Yang Y, Huang P, Cai W.

Mol Pharm. 2017 Oct 2;14(10):3239-3247. doi: 10.1021/acs.molpharmaceut.7b00216. Epub 2017 Sep 6.

8.

89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.

England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120. doi: 10.1007/s00259-017-3803-4. Epub 2017 Aug 19.

9.

Biocompatibility and in vivo operation of implantable mesoporous PVDF-based nanogenerators.

Yu Y, Sun H, Orbay H, Chen F, England CG, Cai W, Wang X.

Nano Energy. 2016 Sep;27:275-281. doi: 10.1016/j.nanoen.2016.07.015. Epub 2016 Jul 16.

10.

CD38 as a PET Imaging Target in Lung Cancer.

Ehlerding EB, England CG, Jiang D, Graves SA, Kang L, Lacognata S, Barnhart TE, Cai W.

Mol Pharm. 2017 Jul 3;14(7):2400-2406. doi: 10.1021/acs.molpharmaceut.7b00298. Epub 2017 Jun 8.

11.

Radiomanganese PET Detects Changes in Functional β-Cell Mass in Mouse Models of Diabetes.

Hernandez R, Graves SA, Gregg T, VanDeusen HR, Fenske RJ, Wienkes HN, England CG, Valdovinos HF, Jeffery JJ, Barnhart TE, Severin GW, Nickles RJ, Kimple ME, Merrins MJ, Cai W.

Diabetes. 2017 Aug;66(8):2163-2174. doi: 10.2337/db16-1285. Epub 2017 May 17.

12.

ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.

Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W.

Mol Pharm. 2017 May 1;14(5):1782-1789. doi: 10.1021/acs.molpharmaceut.7b00056. Epub 2017 Apr 12.

13.

ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.

Luo H, England CG, Goel S, Graves SA, Ai F, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W.

Mol Pharm. 2017 May 1;14(5):1646-1655. doi: 10.1021/acs.molpharmaceut.6b01123. Epub 2017 Mar 24.

14.

Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.

Jiang D, Im HJ, Sun H, Valdovinos HF, England CG, Ehlerding EB, Nickles RJ, Lee DS, Cho SY, Huang P, Cai W.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1296-1305. doi: 10.1007/s00259-017-3663-y. Epub 2017 Mar 6.

15.

Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation.

Shi S, Xu C, Yang K, Goel S, Valdovinos HF, Luo H, Ehlerding EB, England CG, Cheng L, Chen F, Nickles RJ, Liu Z, Cai W.

Angew Chem Int Ed Engl. 2017 Mar 6;56(11):2889-2892. doi: 10.1002/anie.201610649. Epub 2017 Feb 7.

16.

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

England CG, Rui L, Cai W.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):517-532. doi: 10.1007/s00259-016-3560-9. Epub 2016 Nov 14. Review.

17.

CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.

Hernandez R, Sun H, England CG, Valdovinos HF, Ehlerding EB, Barnhart TE, Yang Y, Cai W.

Theranostics. 2016 Aug 8;6(11):1918-33. doi: 10.7150/thno.15568. eCollection 2016.

18.

DNA nanomaterials for preclinical imaging and drug delivery.

Jiang D, England CG, Cai W.

J Control Release. 2016 Oct 10;239:27-38. doi: 10.1016/j.jconrel.2016.08.013. Epub 2016 Aug 13. Review.

19.

Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.

Goel S, England CG, Chen F, Cai W.

Adv Drug Deliv Rev. 2017 Apr;113:157-176. doi: 10.1016/j.addr.2016.08.001. Epub 2016 Aug 9. Review.

20.

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W.

J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. Epub 2016 Aug 4.

21.

Molecular Imaging of Immunotherapy Targets in Cancer.

Ehlerding EB, England CG, McNeel DG, Cai W.

J Nucl Med. 2016 Oct;57(10):1487-1492. Epub 2016 Jul 28. Review.

22.

Dual-Modality Positron Emission Tomography/Optical Image-Guided Photodynamic Cancer Therapy with Chlorin e6-Containing Nanomicelles.

Cheng L, Kamkaew A, Sun H, Jiang D, Valdovinos HF, Gong H, England CG, Goel S, Barnhart TE, Cai W.

ACS Nano. 2016 Aug 23;10(8):7721-30. doi: 10.1021/acsnano.6b03074. Epub 2016 Jul 28.

23.

ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.

Sun H, England CG, Hernandez R, Graves SA, Majewski RL, Kamkaew A, Jiang D, Barnhart TE, Yang Y, Cai W.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2169-2179. doi: 10.1007/s00259-016-3442-1. Epub 2016 Jun 25.

24.

Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease.

Im HJ, England CG, Feng L, Graves SA, Hernandez R, Nickles RJ, Liu Z, Lee DS, Cho SY, Cai W.

ACS Appl Mater Interfaces. 2016 Jul 20;8(28):17955-63. doi: 10.1021/acsami.6b05840. Epub 2016 Jul 7.

25.

ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors.

Hernandez R, Sun H, England CG, Valdovinos HF, Barnhart TE, Yang Y, Cai W.

Mol Pharm. 2016 Jul 5;13(7):2563-70. doi: 10.1021/acs.molpharmaceut.6b00372. Epub 2016 Jun 10.

26.

Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles.

England CG, Im HJ, Feng L, Chen F, Graves SA, Hernandez R, Orbay H, Xu C, Cho SY, Nickles RJ, Liu Z, Lee DS, Cai W.

Biomaterials. 2016 Sep;100:101-9. doi: 10.1016/j.biomaterials.2016.05.018. Epub 2016 May 21.

27.

Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET.

England CG, Ehlerding EB, Cai W.

J Nucl Med. 2016 Sep;57(9):1331-2. doi: 10.2967/jnumed.116.173963. Epub 2016 May 19. No abstract available.

28.

Quantum dot-NanoLuc bioluminescence resonance energy transfer enables tumor imaging and lymph node mapping in vivo.

Kamkaew A, Sun H, England CG, Cheng L, Liu Z, Cai W.

Chem Commun (Camb). 2016 May 19;52(43):6997-7000. doi: 10.1039/c6cc02764d.

29.

Long circulating reduced graphene oxide-iron oxide nanoparticles for efficient tumor targeting and multimodality imaging.

Xu C, Shi S, Feng L, Chen F, Graves SA, Ehlerding EB, Goel S, Sun H, England CG, Nickles RJ, Liu Z, Wang T, Cai W.

Nanoscale. 2016 Jul 7;8(25):12683-92. doi: 10.1039/c5nr09193d. Epub 2016 Apr 25.

30.

ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.

England CG, Kamkaew A, Im HJ, Valdovinos HF, Sun H, Hernandez R, Cho SY, Dunphy EJ, Lee DS, Barnhart TE, Cai W.

Mol Pharm. 2016 Jun 6;13(6):1958-66. doi: 10.1021/acs.molpharmaceut.6b00132. Epub 2016 Apr 26.

31.

NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence.

England CG, Ehlerding EB, Cai W.

Bioconjug Chem. 2016 May 18;27(5):1175-1187. doi: 10.1021/acs.bioconjchem.6b00112. Epub 2016 Apr 19. Review.

32.

Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.

Luo H, England CG, Shi S, Graves SA, Hernandez R, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W.

Clin Cancer Res. 2016 Aug 1;22(15):3821-30. doi: 10.1158/1078-0432.CCR-15-2054. Epub 2016 Mar 29.

33.

Evaluation of uptake and distribution of gold nanoparticles in solid tumors.

England CG, Gobin AM, Frieboes HB.

Eur Phys J Plus. 2015 Nov 1;130(11). pii: 231. Epub 2015 Nov 19.

34.

An interdisciplinary computational/experimental approach to evaluate drug-loaded gold nanoparticle tumor cytotoxicity.

Curtis LT, England CG, Wu M, Lowengrub J, Frieboes HB.

Nanomedicine (Lond). 2016 Feb;11(3):197-216. doi: 10.2217/nnm.15.195.

35.

Molecular Imaging of Pancreatic Cancer with Antibodies.

England CG, Hernandez R, Eddine SB, Cai W.

Mol Pharm. 2016 Jan 4;13(1):8-24. doi: 10.1021/acs.molpharmaceut.5b00626. Epub 2015 Dec 10. Review.

36.

Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas.

Yang Y, Hernandez R, Rao J, Yin L, Qu Y, Wu J, England CG, Graves SA, Lewis CM, Wang P, Meyerand ME, Nickles RJ, Bian XW, Cai W.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6525-34. doi: 10.1073/pnas.1502648112. Epub 2015 Nov 9.

37.

PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.

Luo H, England CG, Graves SA, Sun H, Liu G, Nickles RJ, Cai W.

J Nucl Med. 2016 Feb;57(2):285-90. doi: 10.2967/jnumed.115.166462. Epub 2015 Nov 5.

38.

Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry.

Luo H, Hernandez R, Hong H, Graves SA, Yang Y, England CG, Theuer CP, Nickles RJ, Cai W.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12806-11. doi: 10.1073/pnas.1509667112. Epub 2015 Sep 28.

39.

Novel Preparation Methods of (52)Mn for ImmunoPET Imaging.

Graves SA, Hernandez R, Fonslet J, England CG, Valdovinos HF, Ellison PA, Barnhart TE, Elema DR, Theuer CP, Cai W, Nickles RJ, Severin GW.

Bioconjug Chem. 2015 Oct 21;26(10):2118-24. doi: 10.1021/acs.bioconjchem.5b00414. Epub 2015 Sep 10.

40.

Detection of Phosphatidylcholine-Coated Gold Nanoparticles in Orthotopic Pancreatic Adenocarcinoma using Hyperspectral Imaging.

England CG, Huang JS, James KT, Zhang G, Gobin AM, Frieboes HB.

PLoS One. 2015 Jun 5;10(6):e0129172. doi: 10.1371/journal.pone.0129172. eCollection 2015.

41.

Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.

Hernandez R, Czerwinski A, Chakravarty R, Graves SA, Yang Y, England CG, Nickles RJ, Valenzuela F, Cai W.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1859-68. doi: 10.1007/s00259-015-3085-7. Epub 2015 May 28.

42.

HaloTag technology: a versatile platform for biomedical applications.

England CG, Luo H, Cai W.

Bioconjug Chem. 2015 Jun 17;26(6):975-86. doi: 10.1021/acs.bioconjchem.5b00191. Epub 2015 May 22. Review.

43.

A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity.

England CG, Ng CF, van Berkel V, Frieboes HB.

Curr Drug Targets. 2015;16(10):1057-87. Review.

PMID:
25944016
44.

Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles.

England CG, Miller MC, Kuttan A, Trent JO, Frieboes HB.

Eur J Pharm Biopharm. 2015 May;92:120-9. doi: 10.1016/j.ejpb.2015.02.017. Epub 2015 Mar 7.

45.

Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.

Zeiderman MR, Egger ME, Kimbrough CW, England CG, Dupre TV, McMasters KM, McNally LR.

J Surg Res. 2014 Jul;190(1):111-8. doi: 10.1016/j.jss.2014.02.021. Epub 2014 Feb 20.

46.

Enhanced penetration into 3D cell culture using two and three layered gold nanoparticles.

England CG, Priest T, Zhang G, Sun X, Patel DN, McNally LR, van Berkel V, Gobin AM, Frieboes HB.

Int J Nanomedicine. 2013;8:3603-17. doi: 10.2147/IJN.S51668. Epub 2013 Oct 1.

47.

Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.

Lee JJ, Huang J, England CG, McNally LR, Frieboes HB.

PLoS Comput Biol. 2013;9(9):e1003231. doi: 10.1371/journal.pcbi.1003231. Epub 2013 Sep 19.

Supplemental Content

Loading ...
Support Center